Literature DB >> 16758308

Quasispecies as predictive response factors for antiviral treatment in patients with chronic hepatitis C.

Javier Salmerón1, Paloma Muñoz De Rueda, Angela Ruiz-Extremera, Jorge Casado, Carlos Huertas, Maria Del Carmen Bernal, Luis Rodríguez, Angel Palacios.   

Abstract

The object of this study was to evaluate the viral factor, especially the quasispecies, as predictive of sustained virologic response. We studied the quasispecies, genotype, viral load, and hepatitis C (HCV) cAg in 41 patients with chronic hepatitis C treated with interferon and in 84 with interferon and ribavirin. In the interferon group, responders presented a lower viral load. From logistic regression analysis of patients treated with interferon plus ribavirin, independent predictors for sustained virologic response were genotype 3a, a low baseline viral load and <or=3 bands quasispecies. Genotype and viral load presented higher specificity and positive predictive value than did quasispecies. In patients with genotype 1, viral load <or=5 x 10(5) IU/mL and <or=3 quasispecies were predictive for sustained virologic response. In conclusion, the predictive factors of virologic response are genotype, viral load, and quasispecies. Quasispecies did not improve on the genotype or the viral load as predictors of virologic response.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16758308     DOI: 10.1007/s10620-006-9347-2

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  38 in total

1.  The scientific challenge of hepatitis C.

Authors:  J Cohen
Journal:  Science       Date:  1999-07-02       Impact factor: 47.728

2.  Combined therapy with interferon and ribavirin in chronic hepatitis C does not affect serum quasispecies diversity.

Authors:  S Sookoian; G Castaño; B Frider; J Cello; R Campos; D Flichman
Journal:  Dig Dis Sci       Date:  2001-05       Impact factor: 3.199

3.  Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients.

Authors:  Y Kanazawa; N Hayashi; E Mita; T Li; H Hagiwara; A Kasahara; H Fusamoto; T Kamada
Journal:  Hepatology       Date:  1994-11       Impact factor: 17.425

4.  Dynamics of viral quasispecies during interferon therapy in non responder chronic hepatitis C patients.

Authors:  M A Thelu; M Baud; V Leroy; J M Seigneurin; J P Zarski
Journal:  J Clin Virol       Date:  2001-08       Impact factor: 3.168

5.  Evaluation of a new enzyme immunoassay for hepatitis C virus (HCV) core antigen with clinical sensitivity approximating that of genomic amplification of HCV RNA.

Authors:  E Tanaka; C Ohue; K Aoyagi; K Yamaguchi; S Yagi; K Kiyosawa; H J Alter
Journal:  Hepatology       Date:  2000-08       Impact factor: 17.425

6.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

7.  Fluctuation of hepatitis C virus quasispecies in persistent infection and interferon treatment revealed by single-strand conformation polymorphism analysis.

Authors:  N Enomoto; M Kurosaki; Y Tanaka; F Marumo; C Sato
Journal:  J Gen Virol       Date:  1994-06       Impact factor: 3.891

8.  Inferred hepatitis C virus quasispecies diversity is influenced by choice of DNA polymerase in reverse transcriptase-polymerase chain reactions.

Authors:  B Mullan; E Kenny-Walsh; J K Collins; F Shanahan; L J Fanning
Journal:  Anal Biochem       Date:  2001-02-15       Impact factor: 3.365

9.  Hepatitis C viral complexity detected by single-strand conformation polymorphism and response to interferon therapy.

Authors:  T Moribe; N Hayashi; Y Kanazawa; E Mita; H Fusamoto; M Negi; T Kaneshige; H Igimi; T Kamada; K Uchida
Journal:  Gastroenterology       Date:  1995-03       Impact factor: 22.682

10.  Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection.

Authors:  Thomas J Chambers; Xiaofeng Fan; Deborah A Droll; Edgardo Hembrador; Tiffany Slater; Michael W Nickells; Lynn B Dustin; Adrian M Dibisceglie
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

View more
  3 in total

1.  Neutralizing antibodies in patients with chronic hepatitis C, genotype 1, against a panel of genotype 1 culture viruses: lack of correlation to treatment outcome.

Authors:  Jannie Pedersen; Tanja B Jensen; Thomas H R Carlsen; Kristian Schønning; Peer Brehm Christensen; Alex Lund Laursen; Henrik Krarup; Jens Bukh; Nina Weis
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

2.  Analysis of HCV quasispecies dynamic under selective pressure of combined therapy.

Authors:  Ana C G Jardim; Cíntia Bittar; Renata P A Matos; Lílian H T Yamasaki; Rafael A Silva; João R R Pinho; Roberta M Fachini; Claudia M A Carareto; Isabel M V G de Carvalho-Mello; Paula Rahal
Journal:  BMC Infect Dis       Date:  2013-02-01       Impact factor: 3.090

3.  Correlation between pre-treatment quasispecies complexity and treatment outcome in chronic HCV genotype 3a.

Authors:  Isabelle Moreau; John Levis; Orla Crosbie; Elizabeth Kenny-Walsh; Liam J Fanning
Journal:  Virol J       Date:  2008-07-09       Impact factor: 4.099

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.